In addition, we show a significant behavioral effect of reduced dosage, rather than total ablation, of Cacna1c. This is important as genetic variants associated with increased risk for psychiatric disorders in humans are anticipated to affect Cacna1c dosage and not to produce a total ablation of the gene (which is not compatible with viability).9,10,13. The gene discussed is CACNA1C; the disease is psychiatric disorder.